Nintedanib (Ofev, Boehringer Ingelheim Pharmaceuticals) has been approved for the treatment of chronic fibrosing interstitial lung disease with a progressive phenotype.
Flu season is still going strong, with at least 34 million cases to date. Get updates on management, with an emphasis on protecting high-risk patients, in this timely,
expert-led program.
expert-led program.